相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The association between tumor mutational burden and prognosis is dependent on treatment context
Cristina Valero et al.
NATURE GENETICS (2021)
Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy
Matthias Gromeier et al.
NATURE COMMUNICATIONS (2021)
Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization
Ana Rita Pombo Antunes et al.
NATURE NEUROSCIENCE (2021)
Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas
Yao Yu et al.
NEURO-ONCOLOGY (2021)
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
NEURO-ONCOLOGY (2021)
Glial and myeloid heterogeneity in the brain tumour microenvironment
Brian M. Andersen et al.
NATURE REVIEWS CANCER (2021)
Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas
Mirco Friedrich et al.
NATURE CANCER (2021)
CTLA-4 correlates with immune and clinical characteristics of glioma
Fangkun Liu et al.
CANCER CELL INTERNATIONAL (2020)
IDH mutation in glioma: molecular mechanisms and potential therapeutic targets
Sue Han et al.
BRITISH JOURNAL OF CANCER (2020)
Single-Cell Mapping of Human Brain Cancer Reveals Tumor-Specific Instruction of Tissue-Invading Leukocytes
Ekaterina Friebel et al.
CELL (2020)
Interrogation of the Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alterations of Immune Cells
Florian Klemm et al.
CELL (2020)
The Emerging Role of Myeloid-Derived Suppressor Cells in the Glioma Immune Suppressive Microenvironment
Yajing Mi et al.
FRONTIERS IN IMMUNOLOGY (2020)
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma The CheckMate 143 Phase 3 Randomized Clinical Trial
David A. Reardon et al.
JAMA ONCOLOGY (2020)
Mechanisms and therapeutic implications of hypermutation in gliomas
Mehdi Touat et al.
NATURE (2020)
Higher cytolytic score correlates with an immunosuppressive tumor microenvironment and reduced survival in glioblastoma
Alexander F. Haddad et al.
SCIENTIFIC REPORTS (2020)
Prognostic and predictive value of an immune infiltration signature in diffuse lower-grade gliomas
Lai-Rong Song et al.
JCI INSIGHT (2020)
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Robert M. Samstein et al.
NATURE GENETICS (2019)
Current state of immunotherapy for glioblastoma
Michael Lim et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
LGG-58. A PHASE II TRIAL OF POLY-ICLC IN THE MANAGEMENT OF RECURRENT OR PROGRESSIVE PEDIATRIC LOW GRADE GLIOMAS (NCT01188096): PRELIMINARY ANALYSIS
Dolly Aguilera et al.
NEURO-ONCOLOGY (2018)
Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors
Pakawat Chongsathidkiet et al.
NATURE MEDICINE (2018)
Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomase
Gary Kohanbash et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Correlation of immune phenotype with IDH mutation in diffuse glioma
Anna Sophie Berghoff et al.
NEURO-ONCOLOGY (2017)
Tumor Mutational Burden and Response Rate to PD-1 Inhibition
Mark Yarchoan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq
Andrew S. Venteicher et al.
SCIENCE (2017)
Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment
Soren Muller et al.
GENOME BIOLOGY (2017)
Tumor Purity as an Underlying Key Factor in Glioma
Chuanbao Zhang et al.
CLINICAL CANCER RESEARCH (2017)
Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies
Sarah T. Garber et al.
NEURO-ONCOLOGY (2016)
Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM
Dimitrios Mathios et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
A Probabilistic Atlas of Diffuse WHO Grade II Glioma Locations in the Brain
Sarah Parisot et al.
PLOS ONE (2016)
Structural and functional features of central nervous system lymphatic vessels
Antoine Louveau et al.
NATURE (2015)
The odds of immunotherapy success
Matthew M. Gubin et al.
SCIENCE (2015)
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Eliezer M. Van Allen et al.
SCIENCE (2015)
Systematic pan-cancer analysis of tumour purity
Dvir Aran et al.
NATURE COMMUNICATIONS (2015)
Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma
Serena Pellegatta et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2015)
Induction of Robust Type-I CD8+ T-cell Responses in WHO Grade 2 Low-Grade Glioma Patients Receiving Peptide-Based Vaccines in Combination with Poly-ICLC
Hideho Okada et al.
CLINICAL CANCER RESEARCH (2015)
Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma
Anna Sophie Berghoff et al.
NEURO-ONCOLOGY (2015)
A vaccine targeting mutant IDH1 induces antitumour immunity
Theresa Schumacher et al.
NATURE (2014)
Immunity, Inflammation, and Cancer
Sergei I. Grivennikov et al.
CELL (2010)
IDH1 and IDH2 Mutations in Gliomas
Hai Yan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas
Amy B. Heimberger et al.
CLINICAL CANCER RESEARCH (2008)
Surgery insight: the role of surgery in the management of low-grade gliomas
Nader Pouratian et al.
NATURE CLINICAL PRACTICE NEUROLOGY (2007)
分享论文
